MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

Core Insights - MapLight Therapeutics shares opened 11.8% above their offer price during their Nasdaq debut, indicating strong market interest and demand for the company's stock [1] - The initial valuation of MapLight Therapeutics reached $787 million, reflecting investor confidence in the drug developer's potential [1] Company Summary - MapLight Therapeutics is a drug developer that has recently gone public, showcasing its growth potential through a successful Nasdaq debut [1] - The company's stock performance on its first day suggests a positive reception from investors, which may indicate future opportunities for capital raising and expansion [1]